These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 15470802)

  • 21. Biological profiling of prospective antidepressant response in major depressive disorder: Associations with (neuro)inflammation, fatty acid metabolism, and amygdala-reactivity.
    Mocking RJT; Nap TS; Westerink AM; Assies J; Vaz FM; Koeter MWJ; Ruhé HG; Schene AH
    Psychoneuroendocrinology; 2017 May; 79():84-92. PubMed ID: 28262603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study.
    DeBattista C; Doghramji K; Menza MA; Rosenthal MH; Fieve RR;
    J Clin Psychiatry; 2003 Sep; 64(9):1057-64. PubMed ID: 14628981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.
    Keller M; Montgomery S; Ball W; Morrison M; Snavely D; Liu G; Hargreaves R; Hietala J; Lines C; Beebe K; Reines S
    Biol Psychiatry; 2006 Feb; 59(3):216-23. PubMed ID: 16248986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.
    Nierenberg AA; Ostacher MJ; Calabrese JR; Ketter TA; Marangell LB; Miklowitz DJ; Miyahara S; Bauer MS; Thase ME; Wisniewski SR; Sachs GS
    Am J Psychiatry; 2006 Feb; 163(2):210-6. PubMed ID: 16449473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2.
    Nakamura A; Mihara K; Nagai G; Kagawa S; Suzuki T; Nemoto K; Kondo T
    Ther Drug Monit; 2016 Jun; 38(3):379-82. PubMed ID: 26829597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression.
    McElroy SL; Zarate CA; Cookson J; Suppes T; Huffman RF; Greene P; Ascher J
    J Clin Psychiatry; 2004 Feb; 65(2):204-10. PubMed ID: 15003074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paroxetine and the FDA.
    Brent DA
    J Am Acad Child Adolesc Psychiatry; 2004 Feb; 43(2):127-8. PubMed ID: 14971062
    [No Abstract]   [Full Text] [Related]  

  • 28. The role of L-methylfolate in depressive disorders.
    Farah A
    CNS Spectr; 2009 Jan; 14(1 Suppl 2):2-7. PubMed ID: 19169195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder.
    Bauer M; Thase ME; Liu S; Earley W; Eriksson H
    J Psychopharmacol; 2015 May; 29(5):565-74. PubMed ID: 25257148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials.
    Carpenter DJ; Fong R; Kraus JE; Davies JT; Moore C; Thase ME
    J Clin Psychiatry; 2011 Nov; 72(11):1503-14. PubMed ID: 21367354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paroxetine and the FDA.
    Riddle MA
    J Am Acad Child Adolesc Psychiatry; 2004 Feb; 43(2):128-30. PubMed ID: 14964296
    [No Abstract]   [Full Text] [Related]  

  • 33. Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial.
    Rapaport MH; Lydiard RB; Pitts CD; Schaefer D; Bartolic EI; Iyengar M; Carfagno M; Lipschitz A
    J Clin Psychiatry; 2009 Jan; 70(1):46-57. PubMed ID: 19026248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical features and drug induced side effects in early versus late antidepressant responders.
    Fabbri C; Marsano A; Balestri M; De Ronchi D; Serretti A
    J Psychiatr Res; 2013 Oct; 47(10):1309-18. PubMed ID: 23800418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lamotrigine treatment of adolescents with unipolar and bipolar depression: a retrospective chart review.
    Shon SH; Joo Y; Lee JS; Kim HW
    J Child Adolesc Psychopharmacol; 2014 Jun; 24(5):285-7. PubMed ID: 24813210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
    Chauvet-Gélinier JC
    Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paroxetine and the FDA.
    Connor DF
    J Am Acad Child Adolesc Psychiatry; 2004 Feb; 43(2):127. PubMed ID: 14726715
    [No Abstract]   [Full Text] [Related]  

  • 39. Lamotrigine as an augmentation agent in treatment-resistant depression.
    Barbee JG; Jamhour NJ
    J Clin Psychiatry; 2002 Aug; 63(8):737-41. PubMed ID: 12197456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
    Iovieno N; Papakostas GI
    J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.